CDXS 250117 7.50C (CDXS250117C7500) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

CDXS250117C7500

Watchlist

0.20
0.000.00%

15min DelayTrading Dec 18 15:26 ET

0.00High0.00Low

Intraday

5D
Daily

News

Codexis, Inc.'s (NASDAQ:CDXS) High Institutional Ownership Speaks for Itself as Stock Continues to Impress, up 17% Over Last Week
Yahoo FinanceDec 14 07:14 ET
Is Codexis (NASDAQ:CDXS) Weighed On By Its Debt Load?
Simply Wall StDec 10 07:06 ET
Synthetic Biology Focused Insights Report 2024-2029 With Competitive Analysis of 38 Vendors - Agilent, Codexis, Eurofins Scientific, Illumina, Novozymes, and Thermo Fisher Scientific Lead - ResearchAndMarkets.com
BusinesswireDec 9 14:18 ET
Cantor Fitzgerald Maintains Codexis(CDXS.US) With Buy Rating, Maintains Target Price $11
Moomoo NewsNov 22 08:31 ET · Ratings
Biofuel Enzyme Global Market Overview 2021-2024 & 2030 With Competitive Analysis of AB Enzymes, BASF, Codexis, DuPont De Nemours, Iogen, Koinklijke, Novonesis, and Transbiodiesel - ResearchAndMarkets.com
BusinesswireNov 22 07:52 ET
Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference
GlobeNewswireNov 19 16:05 ET

Comments

Teddy123

Oct 10 21:41

financial results for the third quarter of 2024 on Thursday, October 31, 2024,

$Codexis (CDXS.US)$
REDWOOD CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the third quarter of 2024 on Thursday, October 31, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm E...

Teddy123

Oct 7 07:27

Codexis secures $31 million to extend cash runwayInvesting.comPublished 10/02/2024, 04:16 PM

$Codexis (CDXS.US)$
Codexis is on the verge of launching an innovative platform for the efficient production of siRNA therapeutics, known as the ECO Synthesis™ Manufacturing Platform. The company has presented promising data that suggests this platform could overcome the scalability and cost limitations of traditional phosphoramidite chemistry used in oligonucleotide synthesis.
investing.com/n...

Teddy123

Oct 3 06:41

Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company

$Codexis (CDXS.US)$
Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company | CDXS Stock News

Jaguar8

Oct 1 06:06

NEWS

$Codexis (CDXS.US)$
Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences
Codexis, Inc. (NASDAQ: CDXS) has entered into a non-exclusive commercial and manufacturing license agreement with Alphazyme , part of Maravai LifeSciences, for multiple enzymes in Codexis' life science enzyme portfolio. The agreement includes licenses for HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes for genomics and dia...

Teddy123

Sep 30 00:17

Wall Street SWOT: Codexis stock pivots to RNAi, analysts see enzyme potentialInvesting.comPublished 09/27/2024, 10:47 AM

$Codexis (CDXS.US)$
Wall Street SWOT: Codexis stock pivots to RNAi, analysts see enzyme potential By Investing.com